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Introduction
In diabetes, increased flux of glucose and free 
fatty acids is associated with mitochondrial reactive 
oxygen species (ROS) overproduction and, as a con-
sequence, increased oxidative stress, which results
from an imbalance in redox state in which pro-oxi-
dants overwhelm antioxidant capacity, may therefore
contribute significantly to disease mechanisms [1].
Several biochemical interacting pathways strictly
associated with hyperglycaemia (glucose auto-oxida-
tion, non-enzymatic protein glycation, mitochondrial
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Abstract
Oxidative stress has been implicated as a mechanism underlying hyperglycaemia-associated cellular damage and
could play a role in the development of diabetes-related complications. This study aimed to evaluate the signifi-
cance of changes in oxidant–antioxidant status in 176 child and adolescent diabetic patients at clinical onset, dur-
ing disease progression and when early microvascular complications appeared. Indicative lipid and protein oxida-
tion markers and antioxidant defence activity were measured in plasma and correlated with clinical data, diabetes
duration, long-term glycometabolic control and serum lipids. Compared with their respective age-matched controls,
diabetic patients had greater oxidative damage to lipids and proteins, demonstrated through the analysis of
hydroperoxides, lipoperoxides and oxidation protein products, all of which were significantly raised at onset,
decreased during the first 1.5 years of evolution and rose progressively thereafter. Plasma levels of oxidizable lipids
were significantly associated with lipid and protein oxidation products. Overall, plasma antioxidant capacity was sig-
nificantly and consistently lower from clinical onset onwards. These results suggest that insulin therapy in the first
year improved metabolic and oxidant homeostasis and consequently hyperglycaemia-derived biomolecular oxida-
tive damage. Diabetes-associated hyperlipidaemia is related to lipid and protein oxidation processes, which sup-
ports the concept of glucose toxicity and lipotoxicity being interrelated. The greatest increase in lipid and protein
oxidative damage biomarkers in young diabetic patients with premature microangiopathy points to oxidative stress
as a possible contributing mechanism of microvascular dysfunction. Consequently, tight lipid and glycometabolic
control may have therapeutic potential by diminishing oxidative tissue-damaging effects of hyperglycaemia.
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ROS overproduction and activation of protein kinase C,
nitric oxide synthase, xanthine oxidase, aldose reductase
and the polyol pathway) boost ROS generation which
provokes oxidative stress in diabetes [2–7]. Type 1 
diabetes mellitus (T1DM) is one of the most common
chronic disorders in children and adolescents in
whom an early onset of microvascular complications
is a cause for concern. Although hyperglycaemia
constitutes the main cause of complications in dia-
betes and good glycaemic control reduces their rate
of development and progression, as established in
the conclusions of the Diabetes Control and
Complications Trial Research Group [8], other genet-
ic or metabolic factors also appear to play a role in
the pathogenesis of vascular diabetes complications.
Oxidative stress is believed to be associated with
hyperglycaemia-mediated vascular dysfunction and,
therefore, implicated in the early development of
complications [4, 9, 10]. In T1DM, insulin deficiency
not only provokes high blood glucose levels but also
lipid metabolism alterations, resulting in perturba-
tions in metabolic homeostasis, with ensuing rises in
substrate concentrations in plasma or other tissues.
This excess of carbohydrate and lipids in the blood-
stream could be a problem per se, since an overload
of peroxidizable substrates in the circulation may be
an underlying pathogenic mechanism related to dep-
osition and oxidation of lipoproteins in the vascular
wall and contribute to the development of diabetes-
related complications. Indeed, patients with diabetes
have a two- to five-fold increased risk of coronary
atherosclerosis that is associated with diabetes-
induced abnormalities in plasma lipids and lipopro-
tein metabolism [11, 12].
Whether oxidative stress plays any role in the pre-
mature development of angiopathy in young diabetic
patients remains unclear. In an attempt to elucidate
this question and delve further into the pathophysio-
logical processes, we aimed to assess whether
increased blood levels of oxidative stress biomarkers
at onset in diabetic children fluctuate in the course of
the disease and when complications appear,
whether dyslipidaemia implies greater susceptibility
to oxidation, and if so to what extent, and whether it
is related to weakened antioxidant activity or to the
glycometabolic control of the disease. With these
aims in mind, indicative markers of lipoperoxidation,
protein oxidation and changes in antioxidant defence
activity were studied in plasma of young diabetic
patients at different time points and correlated with
diabetes-associated metabolic abnormalities, long-term
metabolic control parameters, diabetes duration and
the premature appearance of complications.We
focused on analysing molecular oxidative damage,
which has been increasingly postulated as a major
contributor to the pathogenesis of the vascular injury
occurring in diabetes; nonetheless, evidence support-
ing this hypothesis would be further strengthened by
the contribution of new findings stemming from stud-
ies on oxidative process evolution in children.
Patients and methods 
Patients 
This study was conducted in 176 children, adolescents and
young adults with T1DM and 140 healthy control individu-
als matched for sex, age and body mass index age [CR].
For this study in which diabetic patients were studied at
onset and in different periods of disease progression, they
were subgrouped according to diabetes duration into six
subgroups: diabetes onset [DO], disease duration less than
1 and a half years [<1.5D], disease duration from 1.5 to 5
years [1–5D], disease duration from 5 to 10 years [5–10D],
disease duration more than 10 years [>10D], and patients
in the latter group recently diagnosed (<6 months) with clin-
ical symptoms of microvascular complications [+DC]; all
these 34 patients had both persistent microalbuminuria
(defined as an albumin excretion rate >20 mg/min in two of
three overnight urine collections) and background retinopa-
thy. Characteristics of the subgroup of 34 diabetic patients
with clinical symptoms of microvascular complications
were as follows: 30 had clinical symptoms of retinopathy
and nephropathy and four had retinopathy, nephropathy
and neuropathy. At 5 years of diabetes clinical onset
onwards, albuminuria analyses are determined every 6
months, ophthalmologic examination to detect retinopathy
once a year and neurological examination also once a
year. Population characteristics of the study groups are
shown in Table 1. The number of participants followed dur-
ing the different time points of disease evolution was: seven
diabetic children studied in four different time points; twelve
three times; sixty-seven two times and 90 once. The 75 DO
patients were evaluated between 7 and 10 days after clini-
cal onset of diabetes when hydroelectrolytic disorders and
acidosis had returned to normal with therapy; this group of
patients presented the highest levels of glycosylated
haemoglobin (HbA1c) and fructosamine (Table 1). The
remaining five diabetic groups presented similar plasma
values of HbA1c and fructosamine. At the time of sample
extraction, all diabetic patients had plasma bicarbonate 
1354 © 2007 The Authors
Journal compilation © 2007 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
levels within the normal range of 20–23 mEq/l; serum acid-
base electrolytes were also normal, and no traces of
ketones were found in urine in any of the 5 days prior to the 
time blood samples were taken. Diabetic blood samples
were drawn during periodic routine control analyses.
Diabetic patients were not pre-selected at any time and the
HbA1c values obtained at the time of blood extraction were
correlated with biomarkers of oxidative stress. Blood sam-
ples of healthy controls were obtained from blood analyses
prior to minor surgery (hernia, fimosis, wisdom tooth
extractions and minor plastic surgery). Informed consent
was obtained from all the individuals after the purpose and
nature of the study had been explained. All patients were
diagnosed and followed up at the Paediatric Diabetes 
Unit of the Vall d'Hebron Children’s Hospital and were 
invited to participate in the study, approved by the 
Ethics Committee for Clinical Research of the Vall 
d'Hebron Hospital.
Chemicals
All chemicals were analytical grade. Butylated hydroxytoluene
(BHT), 2-thiobarbituric acid (TBA), chloramine-T, potassium
iodide (KI), hydrogen peroxide (H202), 1,1,3,3-tetraethoxy-
propane (TEP), phosphotungstic acid, -Tocopherol, -phyco-
erythrin from Porphirium cruentum (-PE), and 5,5'-dithio-bis-
(2-nitro-benzoic acid) (DTNB) were purchased from 
Sigma Chemical Company (St. Louis, MO, USA). High
Performance Liquid Chromatography (HPLC) grade ace-
tonitrile from Romil (Cambridge, UK) and n-Butanol,
methanol, ethanol and n-Hexane from Merck (Darmstadt,
Germany). Highly-purified water (resistivity = 18 M.cm)
obtained through a Milli-Q water purification system
(Millipore,Bedford, MA, USA) was used for solution prepa-
ration and for the mobile phase. Separation of -tocopherol
was carried out using a Nova-Pak C18 (5 µm) stainless-
steel column (3.9 x 150 mm i.d.) (Waters).The guard col-
umn was packed with the same material. 6-Hydroxy-
2,5,7,8-tetramethylchroman 2-carboxylic acid (TROLOX)
was obtained from Aldrich Chemical Co. (Milwaukee, WI,
USA). 2,2'-azobis-(2-amidinopropane) hydrochloride (AAPH)
was obtained from Polysciences (Warrington, PA, USA).
Triphenylphosphine 99% (TPP) was purchased from
Aldrich (Gillingham, Dorset, UK). Ammonium ferrous sul-
phate in aqueous sulphuric acid and xylenol orange in
methanol were obtained as the commercial preparation
(PeroXOquant quantitative peroxide assay, lipid-compatible
formulation) from Pierce (Rockford, IL, USA). The commer-
cially available synthetic hydroperoxides 5-HpETE and 13-
HPODE were purchased from ICN Biomedicals Inc.
(Aurora, OH, USA). All other general chemicals used were
of the highest purity available.
Blood sample collection,
processing and analytical methods
Venous blood samples were drawn in fasting state into
tubes containing EDTA or heparin and processed immedi-
ately, as previously reported [13–16]. Aliquots of plasma
and washed erythrocytes were stored at  –85°C until prompt
analysis. Analyses of plasma total radical antioxidant
potential (TRAP), oxidizability, total thiols (SH groups) and
plasma lipid hydroperoxides (HPx) were analysed within 1
week. All the above analytical procedures followed those
established by our laboratory and previously described in
detail [13–16]. Plasma lipid peroxide levels were measured
according to an optimized method with modifications previ-
ously introduced by us for acid pH control of the reaction
and extractions of lipids, proteins, glucose and water-solu-
ble aldehydes in plasma [15] and concentrations
expressed as malondialdehyde (MDA) using 1,1,3,3-
tetraethoxypropane as standard (µmol/l). Total lipid
hydroperoxide plasma levels were quantified by
PeroXOquantTM Quantitative Peroxide Assay FOX (ferrous
oxidation/xylenol orange technique), according to the man-
ufacturer's protocols. Plasma HPx concentration in the
samples was determined as a function of the mean
absorbance difference of samples with and without HPx
elimination by TPP at 560 nm using an H2O2 standard
curve in the concentration range of 0–20 µmol/l. Sample
assays were made in triplicate and the acceptable conduc-
tion velocity (CV) had to be under 5%.
Advanced oxidation protein products (AOPP) were meas-
ured by the method described by Witko-Sarsat et al. [17] with
slight modifications. AOPP were determined spectrophoto-
metrically using a plate reader (Model Anthos HTII) and cal-
ibrated with chloramine-T solutions, which in the presence of
KI absorb at 340 nm. AOPP concentrations were expressed
as µmol/l chloramine-T equivalents. The within-run and
between-run CVs were 2.7% and 4.1%, respectively.
Plasma -tocopherol was determined by reversedphase
HPLC with ultraviolet detection at 280 nm (Waters Model
486 tunable absorbance detector) and peak automatic inte-
gration as detailed previously [13–16]. Injection volume
was 50 µl, and flow-rate 2.0 ml/min at room temperature.
Plasma -tocopherol was extracted with hexane.The
mobile phase used was methanol.Tocopherol acetate used
as internal standard and serum calibration standard for
vitamin E analysis were obtained from Chromsystems
(Munich, Germany). The within-run and between-run CVs
were 3.2% and 5.7%, respectively; detection limit was
1.3 µM. Given the clear metabolic relationship between plas-
ma -tocopherol and plasma lipids, we also express -toco-
pherol levels as a ratio of -tocopherol/total lipids (choles-
terol + triglycerides). Plasma lipid profile (total cholesterol,
triglycerides, low-density lipoprotein [LDL], HDL) and uric
acid were measured by quantitative enzymatic assays as
previously reported [18].
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Whole plasma oxidation was assayed spectrophotomet-
rically according to the method of Kontush and Beisiegel
[19]. Plasma oxidizability was measured as an increase in
absorbance at 234 nm known to reflect the level of conju-
gated dienes in samples. Briefly, heparin plasma (20 µl)
was diluted 150-fold with phosphate-buffered saline (PBS)
and its oxidation induced by the radical initiator AAPH 
(330 µM) at 37°C over a period of 20 hrs. Total plasma thiol
levels were measured spectrophotometrically, using DTNB
as described by Hu [20].
Total radical-trapping antioxidant parameter (TRAP)
analyses. Plasma antioxidant activity was measured using
a modification of Glazer's fluorometric assay [21]. The
water-soluble vitamin E analogue Trolox was used as a
standard and AAPH as generator of peroxyl radicals.
Fluorescence was measured at the emission of 565 nm
and excitation of 540 nm.The results were calculated in the
following way: % TRAP = 1– ( abs. sample or Trolox/
abs. blank) x100. TRAP levels were expressed as arbitrary
units equivalent to Trolox antioxidant activity and calculated
from a calibration curve determined daily between the
TRAP percentage and the concentration of the three stan-
dards. The linear regression coefficient of the calibration
curve was never below 0.999. Intra- and inter-day coeffi-
cients of variation were 2.9% and 6.6%, respectively.
Statistical analysis
Statistical analyses were carried out using the STATVIEW 4.5
statistical program (ABACUS Concepts, Berkeley, CA, USA).
Data (expressed as means ± SEMs) were analysed by
one-way ANOVA test. Each group of diabetic patients was
compared with their corresponding age-matched controls.
Linear regression analysis was used to study associations
between variables. P values  0.05 were considered sta-
tistically significant.
Results
Metabolic control parameters
Description of the clinical characteristics, biochemical
and metabolic control parameters of this wide age-
Table 1 Clinical and biochemical characteristics of study subjects
Diabetic patients
Controls At onset [DO] [<1.5D] [1.5–5D] [5–10D] [10–20D] [+DC]
n 140 75 30 48 61 40 34
Age (years, mean ± SD) 13.7±9.3 9.1±3.7 9.7±4.3 12.2±3.8 16.1±4.3 20.1±4.5 25.9±4.3
(Range) (1–30) (1–17) (3–18) (5–22) (7–24) (13-27) (20-36)
Diabetes duration (years) – – 0.88±0.06 3.28±0.16 7.44±0.175 14.7±0.5 18.96±1.1
(Range) (13-32)
HbA1c (%) (4.6–6.6)* 11.6±0.3 8.2±0.2 9.03±0.22 8.7±0.24 8.39±0.29 8.4±0.3
Fructosamine (µM) (180–285)* 488.6±18.7 360.4±18.7 371.4±15.3 399.4±15.3 388.5±12.3 384.4±15.1
Cholesterol (mM) 4.04±0.05 4.8±0.11c 4.2±0.11 4.6±0.11c 4.6±0.11c 4.8±0.14c 4.85±0.17c
Triglycerides (mM) 0.6±0.02 0.81±0.05b 0.6±0.04 0.57±0.03 0.69±0.05 0.97±0.09c 1.17±0.14c,d
Uric acid µM) 239.5±7.1 154±6.2c 190±10.7b 184.6±9.5c 229.6±10.3 204.07±14a 221.4±22.9
-Tocopherol/TL (µM/mM) 5.18±0.09 4.75±0.14a 4.63±0.13a 4.69±0.12a 4.9±0.1 5.15±0.3 4.4±0.27c,d
Data are means ± SEM. *Data in parentheses are normal ranges. aP<0.05, bP<0.005 and cP<0.0001 versus control
subjects. dP<0.05 versus [10–20D]. Subgroups of diabetic patients: diabetes onset [DO], disease duration <1.5 years
[<1.5D], disease duration from 1–5 years [1.5–5D], disease duration from 5–10 years [5–10D], disease duration from
10–20 years [10–20D], patients with microvascular complications [+DC]. TL = Total lipids.
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range group of diabetic patients between disease
onset and up to 20 years of disease evolution and of
the control group are summarized in Table 1. Glycated
haemoglobin (HbA1c) and fructosamine levels were
raised in all diabetic patient subgroups, with the high-
est values being at [DO]; insulin therapy produced a
clear improvement in metabolic control as reflected
by marked reductions in HbA1c and fructosamine.
Plasma cholesterol and triglyceride levels were sig-
nificantly increased at [DO]; however, while triglycerides
remained in normal range during the first 10 years,
rising significantly thereafter, a slight decrease in
cholesterol was observed in the first 1.5 years followed by
a gradual, significant increase over the study period.
Plasma uric acid levels were statistically lower in dia-
betic patients than in controls during the first 5 years,
with uricaemia yielding the lowest values at [DO].
Oxidative stress indices
Plasma HPx, the major initial reaction products of
lipid peroxidation, were significantly raised at [DO]
and decreased during the first 1.5 years of evolution
to normal values, only to rise progressively thereafter
(Fig. 1A). Similarly, concentrations of secondary lipid
peroxidation end products were significantly higher in
plasma of diabetic patients, except for subgroup
[<1.5D], than in age-matched controls (Fig. 1B). From
1.5 years, a significant trend towards greater and
progressive increases in MDA formation was clearly
observed. Single linear regression analyses revealed
significant correlations between plasma levels of oxi-
dizable lipids and lipid peroxide levels (P<0.0001).
Whole plasma oxidation-induced assay was used
to measure changes in the oxidizability of plasma
lipids during evolution of the disease (Fig. 2A).
Plasma oxidizability was significantly higher in dia-
betic patients than in their respective age-matched
controls, except in the (<1.5 D) group, with the most
significant difference being found in samples from
diabetic children at [DO] (P<0.0001). The increase in
conjugated diene formation was proportional to dis-
ease duration. This measurement correlated signifi-
cantly and positively with the sum of concentrations
of the major oxidizable lipids, cholesterol and triglyc-
erides, (Fig. 2B) and with HbA1c (Fig. 2C).
Plasma AOPP, markers of protein oxidation, were
significantly higher (P<0.0005) in samples from [DO],
[5–10D] and [10–20D] groups and higher still in the
group of diabetic patients with complications com-
pared with their respective age-matched controls
(Fig. 3A). Linear regression analysis of plasma AOPP
showed positive correlations with both triglycerides 
(r = 0.42; P<0.0005) and total lipids (Fig. 3B).
Antioxidant capacity
Mean plasma TRAP values were significantly lower
in diabetic patients throughout disease evolution
(Fig. 4A) with the greatest statistical differences
being at [DO], after which there appeared to be a
progressive 10-year partial recovery period with a
sharp decline thereafter. Plasma TRAP values were
significantly lower in samples of diabetic patients with
complications compared with the values of the
[10–20D] subgroup of patients with the same dia-
betes evolution time. Plasma thiol, a parameter of
non-oxidation of protein-SH groups, was significantly
lower in all diabetic patients, with the exception of
subgroup [<1.5D], than in age-matched controls; the
decrease was constant in all groups, although the
more marked loss of SH groups occurred in patients
at [DO] (Fig. 4B). A significant inverse association
was observed between thiols and HbA1c (Fig. 4C).
Concentrations of the liposoluble antioxidant (-toco-
pherol were similar in diabetic patients and controls.
However, (-tocopherol levels corrected by total lipids
were significantly decreased during the first 5 years
of disease evolution and in +DC group (Table 1).
Values of oxidative stress parameters expressed by
diabetic patient subgroups and those of their respec-
tive controls are shown in Table 2. Biochemical and
molecular oxidative damage biomarkers and antioxi-
dant activities in plasma were not affected by age or
pubertal stage in either controls or diabetic patients
(Tables 3A, 3B and 4). Table 4 specifically presents
the data of diabetic patients according to age and
sex and shows there were no differences between
males and females at the ages studied.
Discussion
Oxidative stress and associated oxidative damage
are currently acknowledged as components of
molecular and cellular tissue damage mechanisms
underlying vascular dysfunction in diabetes [22].
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Fig. 1 Plasma levels of Lipid hydroperoxides (A) and Lipid peroxides (B) in young diabetic patients at disease onset
[DO], during the first 20 years of disease progression [four subgroups: <1.5, 1.5–5, 5–10, 10–20], in diabetic patients
with complications [+DC] and in their respective controls. (A) Filled columns: diabetic patients data; open columns: con-
trol data. (A) Filled circles: diabetic patients data; open circles: control data.Values are expressed as mean ± SEM and
were analysed for statistically-significant differences by analysis of variance (ANOVA); P values <0.05 (versus respec-
tive control participants) were considered significant and are shown above each subgroup in the graph.
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Fig. 2 Plasma oxidizability (A)
in young diabetic patients at
disease onset [DO], during the
first 20 years of disease evolu-
tion [four subgroups: <1.5,
1.5–5, 5–10, 10–20], in diabetic
patients with complications
[+DC] and in their respective
controls; filled circles: diabetic
patients data; open circles: con-
trol data. Correlations between
plasma oxidizability values and
total lipid concentrations in
plasma (B) and HbA1c (C).
Values represented are mean ±
SEM and were analysed for sta-
tistically-significant differences
by analysis of variance (ANOVA);
P values <0.05 (versus respective
control subjects) were considered
significant and are shown above
each subgroup in the graph.
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Fig. 3 Plasma advanced oxidation protein products (AOPP) (A) in diabetic patients at disease onset [DO], during the
first 20 years of disease evolution [four subgroups: <1.5, 1.5–5, 5–10, 10–20], in diabetic patients with complications
[+DC] and in their respective controls; filled columns: diabetic patients data; open columns: control data. Correlation
between plasma AOPP and total lipid concentrations in plasma (B). Values are expressed as mean ± SEM and were
analysed for statistically-significant differences by analysis of variance (ANOVA); P values <0.05 (versus respective con-
trol participants) were considered significant and are shown above each subgroup in the graph. *P<0.05 diabetic
patients with complications [+DC] versus [10–20] subgroup of patients.
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Fig. 4 Plasma Total Radical-
trapping Antioxidant Parameter
(TRAP) values (A) and protein
sulphydryl groups (B) in diabet-
ic patients at disease onset
[DO], during the first 20 years
of disease evolution [four sub-
groups: <1.5, 1.5–5, 5–10,
10–20], in diabetic patients with
complications [+DC] and in
their respective controls; Filled
circles: diabetic patients data;
open circles: control data.
Correlation between protein
sulphydryl groups and HbA1c
(C). Data are means ± SEM
and were analysed for statisti-
cally-significant differences by
analysis of variance (ANOVA); P
values <0.05 (versus respective
control participants) were consid-
ered significant and are shown
above each subgroup in the
graph. *P<0.05 diabetic patients
with complications versus [10–20]
subgroup of patients.
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Table 2 Plasma oxidative stress values of diabetic patients and their respective controls
Table 3A Plasma levels of cholesterol, triglycerides, malondialdehyde (MDA), lipid hydroperoxides (HPx) and advanced
oxidation protein products (AOPP) in control subjects
Data are means ± SEM and were analysed for statistically-significant differences by analysis of variance (ANOVA): *p<0.05, 
**p<.01, †P<0.005, ‡ P<0.001, §P<0.0005, •P<0.0001 versus respective control participants.Subgroups of diabetic
patients:diabetes onset [DO], disease duration <1.5 years [<1.5D], disease duration from 1–5 years [1.5–5D], disease duration
from 5–10 years [5–10D], disease duration from 10–20 years [10–20D], patients with microvascular complications [+DC].AOPP
= Advanced Oxidation Protein Products.TRAP = Total Radical-trapping Antioxidant Parameter.
Data are means ± SEM
Controls At onset[DO] Controls [<1.5D] Controls [1.5–5D] Controls [5–10D] Controls [10–20D] Controls [+DC]
Lipid 
hydroperoxides
(µM)
1.6±0.2 3.2±0.9* 1.55±0.2 1.03±0.4 1.4±0.2 1.88±0.6 1.39±0.2 2.8±1.2 1.32±0.3 5.7±1.5• 1.15±0.4 8.4±1.6•
Lipid 
peroxides 
(µM eq.MDA)
1.56±0.04 1.7±0.06† 1.54±0.04 1.73±0.1 1.54±0.04 1.8±0.06† 1.54±0.04 1.87±0.1• 1.53±0.05 1.9±0.1• 1.56±0.1 2.15±0.14•
Oxidizability
(nmol/min) 3.9±0.08 4.97±0.1• 3.9±0.07 4.17±0.2 3.9±0.07 4.5±0.16• 3.92±0.08 4.7±0.18• 3.8±0.1 4.86±0.1§ 4.05±0.2 5.04±0.2*
TRAP (µM) 2426±57 2100±51• 2423±51 2202±33* 2433±42 2286±26* 2440±42 2293±25* 2498±48 2137±98• 2418±140 1792±170•
Protein-SH
groups (µM) 499±12 433±0.1• 505±11 475±11 511±9 472±7** 515±9.7 464±9.8‡ 520±10 463±20** 534±12 455±23**
AOPP (µM) 45.8±2.7 70.1±6.4§ 46.7±2.6 46.7±4.9 48.6±2.4 59±5 50.4±2.5 79.5±9.7§ 55.4±3.3 88.2±11§ 71.6±4.8 126.7±19§
n
Cholesterol
(mM)
Triglycerides
(mM) MDA (µM) HPx (µM) AOPP (µM)
Age (years)
1–12 73 3.9 ± 0.08 0.59 ± 0.02 1.55 ± 0.05 1.6 ± 0.36 51.74 ± 17
13–30 67 4.1 ± 0.08 0.63 ± 0.03 1.51 ± 0.06 1.3 ± 0.32 53.98 ± 16.3
Sex
Male 77 4.03 ± 0.07 0.61 ± 0.02 1.46 ± 0.05 1.39 ± 0.3 54.3 ± 15
Female 63 4.06 ± 0.08 0.6 ± 0.03 1.61 ± 0.05 1.51 ± 0.37 51.3 ± 16.4
Several biochemical pathways, strictly associated
with hyperglycaemia, increase ROS production that
causes oxidative stress in diabetes [2–7] and, fur-
thermore, diabetes-associated dyslipidaemia could
contribute to cell oxidative damage. The results of
this comprehensive study provide evidence that
hyperglycaemia-derived oxidative stress was already
present at DO and almost disappeared during the
first year and a half of insulin treatment. Thus, the
metabolic efficacy of insulin is not limited to its direct
action on glucose homeostasis maintenance; indeed,
insulin exerts other beneficial effects, probably by
reducing levels of free fatty acids and triglycerides,
substrates that are susceptible to lipoperoxidation. As
a consequence of these beneficial effects of insulin,
an improvement in levels of cytotoxic products of
molecular oxidative damage was observed in this
'honeymoon' period. Changes in plasma lipid levels
were in line with those observed in the formation of
lipoperoxidation products (HPx, MDA) with similar
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Table 3B Plasma oxidizability and plasma levels of total sulphydryl (SH) groups, uric acid and Plasma Total Radical-trap-
ping Antioxidant Parameter (TRAP) values in control subjects
Table 4 Biochemical characteristics of diabetic patients according to sex
Data are means ± SEM
Data are means ±SEM.All differences P>0.05.Subgroups of diabetic patients:diabetes onset [DO], disease duration <1.5 years
[<1.5D], disease duration from 1–5 years [1.5–5D], disease duration from 5–10 years [5–10D], disease duration from 10–20 years
[10–20D], patients with microvascular complications [+DC].AOPP = Advanced Oxidation Protein Products.TRAP = Total
Radical-trapping Antioxidant Parameter.
n
Oxidizability
(nmol/min)
-SH groups
(µM)
-tocopherol/
total lipids
Uric acid 
(µM)
TRAP
(mM)
Age (years)
1–12 73 3.98 ± 0.11 490.2 ± 18.3 5.3 ± 0.09 233.5 ± 9.6 2.4 ± 0.8
13–30 67 3.91 ± 0.13 519.3 ± 11.1 5.03 ± 0.18 243.3 ± 10.7 2.5 ± 0.6
Sex
Male 77 3.95 ± 0.12 507.2 ± 14 5.1 ± 0.13 262.1 ± 9.9 2.4 ± 0.5
Female 63 3.93 ± 0.12 510.7 ± 13.7 5.3 ± 0.11 211.8 ± 8.9 2.5 ± 0.7
At onset [DO] [<1.5D] [1.5–5D] [5–10D] [10–20D] [+DC]
Males Females Males Females Males Females Males Females Males Females Males Females
n 39 36 17 13 23 25 34 27 15 25 9 25
HbA1c (%) 11.5±0.4 11.6±0.4 7.9±0.3 8.7±0.2 9.1±0.3 8.8±0.3 8.5±0.3 8.9±0.3 8±0.3 8.8±0.4 8.4±0.4 8.4±0.3
Fructosamine
(µM) 467±37 502±19 391±33 333±16 352±38 384±16 401±18 395±32 391±20 387±15 397±37 380±17
Cholesterol
(mM) 4.9±0.1 4.7±0.1 4.2±0.16 4.2±0.17 4.7±0.2 4.6±0.16 4.5±0.13 4.7±0.2 4.4±0.3 5±0.2 4.96±0.2 4.8±0.2
Triglycerides
(mM) 0.8±0.06 0.8±0.07 0.6±0.03 0.6±0.08 0.5±0.05 0.6±0.04 0.6±0.04 0.8±0.1 0.9±0.2 1±0.09 1.2±0.2 1.15±0.2
Uric acid (µM) 155±7.9 152±9.9 188±15 192±16 191±11 178±15 244±14 213±14 222±14 191±22 240±62 220±17
-Tocopherol/TL
(µM/mM)
4.7±0.19 4.8±0.2 4.7±0.18 4.4±0.2 4.7±0.2 4.6±0.2 4.8±0.13 4.9±0.15 5.4±1.1 4.9±0.2 4±0.6 4.5±0.2
Lipid hydroper-
oxides (µM) 2.8±0.6 3.7±1.9 0.9±0.4 1.2±0.6 1.2±0.4 2.6±1.1 2.5±0.1 3.6±0.12 4.3±1.5 6.9±2.4 9.5±3.9 8.06±1.8
Lipid peroxides
(µM eq. MDA) 1.7±0.07 1.8±0.11 1.6±0.06 1.8±0.12 1.7±0.1 1.9±0.09 1.8±0.09 1.9±0.12 1.96±0.2 1.92±0.1 2.1±0.09 2.16±0.2
Oxidizability
(nmol/min) 4.9±0.1 5.04±0.2 4.2±0.3 4.1±0.2 4.6±0.3 4.4±0.2 4.6±0.2 4.9±0.2 4.8±0.1 5±0.2 4.7±0.4 5.1±0.3
TRAP (µM) 2023±68 2203±71 2196±42 2210±60 2280±32 2291±43 2280±33 2312±40 2255±32 2012±11 1844±31 1778±21
Protein-SH
groups (µM) 446±16 417±19 481±13 471±13 481±11 460±10 470±15 457±13 499±11 427±35 520±17 435±26
AOPP (µM) 63.8±7.3 78.2±11 48.4±6 47±4.8 53.3±8.7 69±8.2 75±8 95±21.5 75±12 100±17 136±37 123±24
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graphic patterns and, again, the nadir was in the
<1.5-year 'honeymoon' period. Linear regression
analyses revealed significant correlations between
plasma levels of oxidizable lipids and total peroxide
levels in diabetic patients alone, which demonstrates
greater oxidizability of plasma lipids in diabetes.
ROS can react with all biological macromolecules,
among the more susceptible of which are PUFA, and
their peroxidation, mostly in membrane phospholipids,
poses a constant threat to cell integrity and function.
Our results showed that both the major initial and end
products of lipoperoxidation were significantly high in
diabetic patients at onset, significantly improved during
the first 1.5 years of insulin treatment and raised pro-
gressively thereafter with the highest values being
found in patients with early diabetic angiopathy. Hence,
oxidative damage to lipids appears to be present at
onset and throughout the course of the disease and to
be associated with the presence of oxidizable lipid sub-
strates in diabetic patients. Dyslipidaemia in diabetes is
considered to be a major modifiable coronary risk fac-
tor [11, 12, 23] and an association between lipoperox-
idation parameters and diabetic angiopathy has been
reported in young adults with early nephropathy [24].
Moreover, a direct effect of triacylglycerols has been
described as a further underlying mechanism of
oxidative stress-mediated lipotoxicity [25].
Lipid peroxidation, a chain reaction that can con-
tinue until substrate is completely consumed or ter-
mination occurs due to antioxidants, is accompanied
by a selective uptake or net consumption of -toco-
pherol which appears to have served to limit, though
clearly not terminate, lipoperoxidation in young
T1DM patients. Greater susceptibility of plasma to 
in vitro oxidation found in these patients correlated
positively with the sum of concentrations of the major
oxidizable lipids and with glycaemic control, which
concurs with reports that LDL from patients with well-
controlled T1DM does not differ in composition or in
susceptibility to in vitro oxidation compared with LDL
from non-diabetic participants [26, 27]. Thus,
increased lipid susceptibility to oxidation appears to
be secondary to poorly controlled diabetes and its
associated hyperlipidaemia, and may account for the
accelerated vascular disease seen in diabetes.
Should an excess of lipids, the substrate under great-
est attack by free radicals, be a major source of
increased oxidative stress in diabetes, this pathogen-
ic pathway could be a therapeutic target for attenuat-
ing molecular oxidative damage, thereby preventing
the acceleration of atherosclerosis from the early
stages of diabetes. Therefore, it is worthwhile consid-
ering the use of statins, the beneficial effects of
which are mainly attributed to their cholesterol-lower-
ing properties, but which also include other possible
pleiotropic effects related to their anti-inflammatory
and antioxidant activities [28, 29] and attenuate high
glucose-induced and diabetes-induced oxidative
stress in vitro and in vivo [30], thereby providing new
insights into oxidative therapy in diabetes.
Oxidative damage to proteins was also clearly
shown to be continuous from onset and throughout
the course of the first 20 years of diabetes evolution
covered by this study. Elevated oxidative protein
damage has been observed in types 1 and 2 dia-
betes [13, 31, 32]. Plasma concentrations of car-
bonylated proteins (by the method based on binding
of 2, 4-dinitrophenyl-hydrozine (DNPH) to protein
carbonyls) have been the most frequently deter-
mined marker of oxidative protein damage and con-
stitute a well-validated method [33]. In the present
study, evidence of protein oxidative stress was
demonstrated by assessment of AOPPs, considered
to be an oxidized albumin index [17], which were
markedly higher (two-fold) in patients with early dia-
betic angiopathy; interestingly, blood levels of these
abnormal products correlated positively with those of
total lipids and with lipid peroxidation by-products in
the whole study cohort. In view of the results of our
present and previous studies, we consider circulating
AOPP levels to be a useful marker for estimating the
degree of protein oxidative damage since they pro-
vide valid information on the early development of
microvascular complications in diabetes and might
be used to monitor the severity and progress of the
disease; these data concur with those found in type
2 DM and recently reported [34]. This noteworthy
finding would point to a role of oxidative injury to pro-
teins in the early development of diabetic microvas-
cular complications, thereby linking protein oxidation
to disease severity, which is plausible since oxidative
damage to proteins is one mechanism by which oxidants
promote inflammatory damage and increase the 
tissue-destructive effects of proteolytic enzymes, all of
which may lead to severe failure of cell biological func-
tions [32]. ROS overload is known to primarily modify
proteins and generate lipid peroxidation-derived reac-
tive aldehydes that, in turn, can also produce second-
ary modifications of proteins [35]. Our findings confirm
that both processes took place in newly-diagnosed
1364 © 2007 The Authors
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young diabetic patients and those with longer standing
disease and support the hypothesis of carbonyl stress
by which diabetes induces a generalized increase in
oxidative modification of proteins together with glycox-
idation and lipoxidation processes which overgenerate
products with cytotoxic effects that disrupt cell metab-
olism [10, 36].
The degree of oxidative stress and the ensuing
endothelial dysfunction might depend on the imbal-
ance between excessive ROS generation and indi-
vidual antioxidant defence activity. This study showed
plasma SH groups to be susceptible to oxidative 
damage, since levels in children with recent-onset
T1DM were the lowest observed in the course of the
disease. Insulin administration boosted recovery of
plasma thiols and it is noteworthy that a significant
inverse relationship was observed between thiol con-
centration and glycometabolic control which, in poor-
ly controlled T1DM patients, may play a role in the
pathogenesis of diabetes complications [37].The pres-
ent work also found overall plasma antioxidant capaci-
ty to be decreased throughout the study period, partic-
ularly in diabetic patients with complications, indicating
a possible complicity between the circulating antioxi-
dant activity and subsequent development of microvas-
cular complications. Human plasma protection against
free radical injury is offered by a wide spectrum of
antioxidants with synergic action. The directly-meas-
ured TRAP value, used to assess chain-breaking
antioxidants as a whole, was decreased in sera of dia-
betic children from clinical onset, improving slightly with
insulin treatment up to >10 years and declining there-
after. Since the ability of serum to delay peroxidation is
largely determined by levels of individual antioxidants
and their relative contributions to antioxidant activity,
low levels of antioxidants, such as sulfhydryl com-
pounds and uric acid, together with an insufficient 
-tocopherol content for the hyperlipidaemia of these
diabetic children, appear to be responsible for the inad-
equate capacity of plasma to protect its environment
from free radical aggression and might account for the
lack of maintenance of the overall redox network in
plasma of diabetic patients [38, 39]. Since uric acid has
been proposed as a powerful antioxidant molecule, the
hypouricaemia found in diabetic children at levels
23–32% lower than in controls in the first 5 years of
childhood diabetes may contribute to loss of physiolog-
ic protection against free radical activity. In addition,
glucose and free radicals have been shown to provoke
structural changes in albumin, resulting in impairment
of its antioxidant properties [40].
The results of this novel and comprehensive study,
which closely followed oxidative stress progression in
children and adolescents with T1DM, provide further
solid evidence-linking oxidative processes to diabetes
and their potential contribution to the prematue devel-
opment of complications. The overall increase in lipid
and protein oxidative damage biomarkers that 
precedes or accompanies the early stages of dia-
betes-related development of complications points to
oxidative stress processes as potential pathogenic
mechanisms, precursors of microvascular alterations
in diabetes. Moreover, we showed that hyperlipi-
daemia caused by diabetes-associated loss of optimal
regulation of lipid metabolism implies greater suscep-
tibility to oxidation that would lead and significantly
contribute to the extent of lipid and protein oxidation,
thereby supporting the concept of glucose toxicity and
lipotoxicity being interrelated. Therefore, concerted
efforts should be made to reduce oxidative lipaemia
and oxidant stress in an attempt to potentially delay
the development and/or progression of early
microvascular complications. Consequently, tight lipid
and glycometabolic control may have therapeutic
potential by diminishing oxidative tissuedamaging
effects of hyperglycaemia.
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